MCID: BLD036
MIFTS: 51

Bile Duct Disease

Categories: Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Bile Duct Disease

MalaCards integrated aliases for Bile Duct Disease:

Name: Bile Duct Disease 12 15
Bile Duct Diseases 43 44 73
Disorder of Bile Duct 12
Bile Duct Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4138
MeSH 44 D001649
NCIt 50 C96716
SNOMED-CT 68 118926004 197455006
UMLS 73 C0005395

Summaries for Bile Duct Disease

MedlinePlus : 43 Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes. Different diseases can block the bile ducts and cause a problem with the flow of bile: Gallstones, which can increase pressure in the gallbladder and cause a gallbladder attack. The pain usually lasts from one to several hours. Cancer Infections Birth defects, such as biliary atresia. It is the most common reason for liver transplants in children in the United States. Inflammation, which can cause scarring. Over time, this can lead to liver failure. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Bile Duct Disease, also known as bile duct diseases, is related to common bile duct disease and cholangitis, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Bile Duct Disease is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Metabolism and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. The drugs Vancomycin and Pinaverium have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and pancreas, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 A bile duct is any of a number of long tube-like structures that carry bile, and is present in most... more...

Related Diseases for Bile Duct Disease

Diseases related to Bile Duct Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
# Related Disease Score Top Affiliating Genes
1 common bile duct disease 33.9 CCK GGT2
2 cholangitis 32.2 ABCB11 ABCB4 ALB GGT1 GPT
3 cholangitis, primary sclerosing 30.4 ABCB4 GGT1 GPT NR1I2
4 sclerosing cholangitis 30.1 ABCB11 ABCB4 ALB GGT1 NR1I2
5 caroli disease 10.9
6 cholestasis, benign recurrent intrahepatic, 1 10.8 ABCB11 ATP8B1
7 cholestasis, progressive familial intrahepatic, 2 10.8 ABCB11 ABCB4 ATP8B1
8 atp8b1 deficiency 10.8 ABCB11 ATP8B1 NR1H4
9 cholestasis, progressive familial intrahepatic, 3 10.8 ABCB11 ABCB4 ATP8B1
10 choledocholithiasis 10.7 ABCB4 ALB GPT
11 kwashiorkor 10.7 ALB GPT
12 hyperbilirubinemia, rotor type 10.6 ABCC2 ALB
13 paralytic ileus 10.6 ALB CCK
14 hepatic encephalopathy 10.6 ALB GPT SLC25A13
15 xanthomatosis 10.5 CYP7A1 NR1H4 NR1I2
16 cerebrotendinous xanthomatosis 10.5 CYP7A1 NR1H4 NR1I2
17 cyclosporiasis 10.5 GGT1 GGT2
18 autoimmune disease of urogenital tract 10.5 ABCB4 ALB GGT2
19 algoneurodystrophy 10.5 GGT1 GGT2
20 dubin-johnson syndrome 10.5 ABCC2 ABCC3 ABCC4
21 cholecystitis 10.5 ABCB4 ALB CCK GPT
22 periampullary adenoma 10.4 GGT1 GGT2
23 viral hepatitis 10.4 ALB GGT1 GPT
24 cholecystolithiasis 10.3 ABCB4 CCK
25 obstructive jaundice 10.3 ALB GGT1 GPT SLC25A13
26 ethmoid sinus cancer 10.3 GGT1 GGT2
27 bilirubin metabolic disorder 10.3 ABCC2 ALB GGT1 GPT
28 hepatitis b 10.2 ALB GGT1 GPT SLC10A1
29 ethmoid sinus adenocarcinoma 10.2 GGT1 GGT2
30 hepatic tuberculosis 10.2 ALB GGT1 GGT2 GPT
31 hepatic coma 10.1 ALB GPT
32 cholelithiasis 10.0 ABCB4 ALB CCK CYP7A1 GPT NR1H4
33 primary biliary cirrhosis 10.0 ABCB4 ABCC3 ALB GGT1 NR1H4
34 biliary atresia 10.0 ALB ATP8B1 GPT NR1H4 SLC10A1 SLC10A2
35 extrahepatic cholestasis 9.9 ABCB4 ABCC2 ABCC3 CYP7A1 GGT1 GPT
36 cholestasis, progressive familial intrahepatic, 1 9.9 ABCB11 ABCB4 ATP8B1 GGT1 NR1H4 SLC10A2
37 cystic fibrosis 9.7
38 cholangiocarcinoma 9.7
39 echinococcosis 9.7
40 intrahepatic cholangiocarcinoma 9.7
41 gastrointestinal system disease 9.6 ABCB11 ALB CCK GGT1 GGT2 NR1I2
42 liver disease 9.5 ABCB11 ABCB4 ALB ATP8B1 GGT1 GPT
43 intrahepatic cholestasis 8.2 ABCB11 ABCB4 ABCC2 ABCC3 ALB ATP8B1
44 cholestasis 7.8 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ATP8B1
45 biliary tract disease 5.8 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ALB

Graphical network of the top 20 diseases related to Bile Duct Disease:



Diseases related to Bile Duct Disease

Symptoms & Phenotypes for Bile Duct Disease

UMLS symptoms related to Bile Duct Disease:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

GenomeRNAi Phenotypes related to Bile Duct Disease according to GeneCards Suite gene sharing:

26 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.99 SLC51B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.99 NR1I2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.99 ABCC3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.99 SLC51B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.99 SLC51B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.99 NR1I2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.99 GGT2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.99 ABCC3 GGT1 GGT2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-131 9.99 GGT2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.99 NR1I2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.99 NR1I2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.99 ABCB11 ABCC3 GGT1 GGT2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.99 ABCC3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.99 SLC10A2 SLC51B
15 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.99 SLC51B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.99 NR1I2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.99 GGT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.99 NR1I2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.99 ABCC3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.99 ABCC3 SLC51B
21 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.99 SLC10A2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.99 NR1I2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.99 SLC51B
24 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.99 ABCC3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.99 ABCB11
26 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.99 GGT2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.99 SLC51B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.99 SLC10A2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.99 ABCB11
30 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.99 SLC10A2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.99 GGT1 GGT2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.99 SLC51B
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.99 SLC10A2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.99 ABCB11
35 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.99 ABCB11
36 Increased shRNA abundance (Z-score > 2) GR00366-A-90 9.99 SLC10A2 SLC51B NR1I2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.99 SLC51B

MGI Mouse Phenotypes related to Bile Duct Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.83 NR1I2 ABCB11 SLC10A2 ABCB4 SLC25A13 ABCC2
2 digestive/alimentary MP:0005381 9.7 SLC10A2 ABCB4 ABCC4 ALB CYP7A1 CYP8B1
3 liver/biliary system MP:0005370 9.4 NR1I2 ABCB11 SLC10A2 ABCB4 SLC25A13 ABCC2

Drugs & Therapeutics for Bile Duct Disease

Drugs for Bile Duct Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 383)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vancomycin Approved Phase 4,Phase 3,Phase 1,Not Applicable 1404-90-6 441141 14969
2 Pinaverium Approved Phase 4,Not Applicable 59995-65-2
3
Etomidate Approved Phase 4 33125-97-2 36339 667484
4
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
5
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
6
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2 2078-54-8 4943
7
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128-13-2 31401
8
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
9
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
10
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
11
Secretin Approved, Investigational Phase 4 108153-74-8
12
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
13
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 443-48-1 4173
14
Meperidine Approved Phase 4,Not Applicable 57-42-1 4058
15
Ceftriaxone Approved Phase 4,Phase 2 73384-59-5 5479530 5361919
16
chenodeoxycholic acid Approved Phase 4,Phase 3,Phase 2,Early Phase 1 474-25-9 10133
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Ofloxacin Approved Phase 4 82419-36-1 4583
19
Abatacept Approved Phase 4 332348-12-6 10237
20
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
21
Sorbitol Approved Phase 4 50-70-4 5780
22
Choline Approved, Nutraceutical Phase 4 62-49-7 305
23
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2 63-68-3 6137
24 Coconut Approved, Nutraceutical Phase 4
25
Tocopherol Approved, Investigational, Nutraceutical Phase 4 1406-66-2 14986
26
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
27
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
28 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Anticonvulsants Phase 4,Phase 3,Not Applicable
31 Autonomic Agents Phase 4,Phase 3,Phase 1,Not Applicable
32 Bromides Phase 4,Phase 3,Not Applicable
33 calcium channel blockers Phase 4,Phase 3,Not Applicable
34 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Parasympatholytics Phase 4,Phase 3,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Adjuvants, Anesthesia Phase 4,Phase 3
38 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
39 Anesthetics, General Phase 4,Phase 2,Not Applicable
40 Anesthetics, Intravenous Phase 4,Phase 2
41 Anti-Anxiety Agents Phase 4,Phase 3
42 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
43 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
44 Cortisol succinate Phase 4
45 GABA Agents Phase 4,Phase 3,Not Applicable
46 GABA Modulators Phase 4,Not Applicable
47 Hydrocortisone 17-butyrate 21-propionate Phase 4
48 Hydrocortisone acetate Phase 4
49 Hydrocortisone-17-butyrate Phase 4
50 Hypnotics and Sedatives Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 530)
# Name Status NCT ID Phase Drugs
1 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction Unknown status NCT02833103 Phase 4 Danshu Capsules;Pinaverium Bromide
3 Endoscopic Treatment of Difficult Bile Duct Stones: Spyglass + EHL x Balloon Dilation of the Papilla Unknown status NCT02703077 Phase 4
4 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
5 Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children Unknown status NCT02013986 Phase 4 etomidate;midazolam;propofol
6 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
7 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
8 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
9 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
10 The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent Completed NCT01862198 Phase 4
11 A Study of Serial Magnetic Resonance Cholangiopancreatography (MRCP) Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers Completed NCT01134848 Phase 4 Morphine;Neostigmine;0.9% saline;Secretin;0.9% saline
12 Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia Completed NCT02298218 Phase 4 Meloxicam
13 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study Completed NCT01744847 Phase 4
14 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
15 Preventing Cholestasis Using SMOFLipid® Completed NCT01585935 Phase 4 SMOFLIPID;INTRALIPID
16 Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Completed NCT02557360 Phase 4
17 Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis Completed NCT01510860 Phase 4 UDCA (Ursodeoxycholic acid);UDCA (Ursodeoxycholic acid)
18 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
19 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
20 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
21 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
22 WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study Recruiting NCT01543256 Phase 4
23 A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Recruiting NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
24 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
25 A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis Active, not recruiting NCT02464020 Phase 4 Vancomycin
26 Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis Active, not recruiting NCT02078882 Phase 4
27 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
28 Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders Terminated NCT01373918 Phase 4 Intralipid;Intralipid
29 Reduction of Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions Terminated NCT02633384 Phase 4
30 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4 Albumin
31 Compare the Knob-tipped Knife With the Needle Knife in Difficult Biliary Cannulation Unknown status NCT01745978 Phase 3
32 RCT of Steroids Following Kasai Portoenterostomy for Biliary Atresia. Unknown status NCT00539565 Phase 3 prednisolone;placebo
33 Minimization of IntraLipid Versus Omegaven Unknown status NCT01247012 Phase 2, Phase 3
34 Probiotics in Patients With Primary Sclerosing Cholangitis Unknown status NCT00161148 Phase 3 Probiotics
35 Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
36 Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
37 WallFlex Biliary Fully Covered (FC) Benign Stricture Study Unknown status NCT01014390 Phase 3
38 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
39 Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid Unknown status NCT02823366 Phase 3 Fenofibrate;UDCA
40 Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Unknown status NCT02823353 Phase 3 Fenofibrate;UDCA
41 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
42 Newly Designed Fully Covered Metal Stent for the Benign Biliary Stricture Completed NCT00945516 Phase 3
43 Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP) Completed NCT00731198 Phase 3 Drotaverine hydrochloride;Hyoscine-N-butylbromide
44 Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
45 Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction) Completed NCT00471315 Phase 3 Duloxetine
46 Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition Completed NCT02663453 Phase 3 multicomponent lipid emulsion;pure soybean oil lipid emulsion
47 Clinical Outcomes of EUS-guided Biliary Drainage Using Partially or Fully Covered Metallic Stents Completed NCT02114320 Phase 3
48 Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates Completed NCT00846963 Phase 2, Phase 3 Ursodiol;placebo
49 Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC Completed NCT01829698 Phase 3 tauroursodeoxycholic;ursodeoxycholic acid
50 Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct Obstruction Completed NCT00453076 Phase 3

Search NIH Clinical Center for Bile Duct Disease

Cochrane evidence based reviews: bile duct diseases

Genetic Tests for Bile Duct Disease

Anatomical Context for Bile Duct Disease

MalaCards organs/tissues related to Bile Duct Disease:

41
Liver, Lung, Pancreas, Kidney, Bone, Small Intestine, Breast

Publications for Bile Duct Disease

Articles related to Bile Duct Disease:

(show all 18)
# Title Authors Year
1
Gallbladder and bile duct disease in Cystic Fibrosis. ( 28986023 )
2017
2
Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. ( 24555589 )
2014
3
CHOLANGIOSCOPY IN BILE DUCT DISEASE: a case series. ( 25296087 )
2014
4
Echinococcosis mimicking autoimmune or malignant bile duct disease. ( 24022203 )
2013
5
Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients. ( 23085575 )
2013
6
Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). ( 21762903 )
2011
7
Biliary cytokeratin expression but not CD56 (N-CAM) expression aids in the differential diagnosis of non-neoplastic bile duct diseases. ( 20538416 )
2010
8
Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E- NPP3/CD203c/PD-Ibeta/B10/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases. ( 15072822 )
2004
9
Treatment of extrahepatic bile duct disease in infancy and early childhood. ( 11847446 )
2002
10
New approach in diagnosis of bile duct disease with ultrasound and magnetic resonance imaging. ( 28976650 )
1998
11
Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. ( 8201224 )
1994
12
Bile duct disease: prospective comparison of ERCP, CT, and fat suppression MRI. ( 1426853 )
1992
13
Rejection of murine congenic bile ducts: a model for immune-mediated bile duct disease. ( 1537528 )
1992
14
Primary sclerosing cholangitis, a vanishing bile duct disease. ( 3658059 )
1987
15
Radiomanometry in the diagnosis of common bile duct disease. ( 4445925 )
1974
16
Radiomanometry, flow rates, and cholangiography in the evaluation of common bile duct disease. A study of 220 cases. ( 5058873 )
1972
17
Gallbladder and bile duct disease. ( 14392255 )
1955
18
The incidence of common bile duct disease following surgical exploration. ( 14352652 )
1955

Variations for Bile Duct Disease

Expression for Bile Duct Disease

Search GEO for disease gene expression data for Bile Duct Disease.

Pathways for Bile Duct Disease

Pathways related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 ABCB11 ABCB4 ABCC3 ALB CYP7A1 CYP8B1
2
Show member pathways
13.24 ABCB4 ABCC2 ABCC3 ABCC4 ALB ATP8B1
3
Show member pathways
12.15 ABCB11 ABCC3 ALB CYP7A1 CYP8B1 NR1H4
4 11.99 ABCC2 ABCC3 ABCC4 GGT1 GGT2
5
Show member pathways
11.9 ABCB11 ABCB4 ABCC2 SLC10A1 SLCO1A2
6 11.75 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 CYP7A1
7
Show member pathways
11.73 ABCB11 ABCC2 ABCC4 SLCO1A2
8
Show member pathways
11.62 ABCC2 ABCC3 ABCC4
9 11.19 ABCC2 ABCC3 ABCC4
10 11.08 ABCB11 ABCB4 CYP7A1 CYP8B1 NR1H4 SLC10A1
11 11.07 ABCC2 ABCC3 ABCC4
12
Show member pathways
10.97 ABCC2 ABCC3 ABCC4 SLCO1A2
13 10.95 GGT1 GGT2
14 10.91 ABCC2 ABCC3 ABCC4
15 10.84 ABCB11 ABCC2 ABCC3 ABCC4 CYP7A1 NR1H4
16 10.77 ABCB11 ABCB4 ABCC2 ABCC3 CYP7A1 CYP8B1
17 10.75 ABCC3 NR1I2
18 10.67 ABCC2 NR1I2
19 10.54 ABCC2 ABCC3

GO Terms for Bile Duct Disease

Cellular components related to Bile Duct Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.67 ABCB4 ABCC2 ATP8B1 SLC10A2
2 integral component of plasma membrane GO:0005887 9.65 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ATP8B1
3 basolateral plasma membrane GO:0016323 9.56 ABCC3 ABCC4 SLC10A1 SLC51B
4 brush border membrane GO:0031526 9.33 ABCB4 ABCC2 ATP8B1
5 intercellular canaliculus GO:0046581 8.8 ABCB11 ABCB4 ABCC2
6 integral component of membrane GO:0016021 10.13 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ATP8B1

Biological processes related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 cholesterol homeostasis GO:0042632 9.72 CYP7A1 NR1H4 NR1I2
2 transmembrane transport GO:0055085 9.65 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 SLC10A1
3 lipid homeostasis GO:0055088 9.61 ABCB4 NR1H4 NR1I2
4 phospholipid translocation GO:0045332 9.58 ABCB4 ATP8B1
5 zymogen activation GO:0031638 9.58 GGT1 GGT2
6 bile acid biosynthetic process GO:0006699 9.58 ABCB11 CYP7A1 CYP8B1
7 response to glucagon GO:0033762 9.57 ABCB4 ABCC2
8 bile acid metabolic process GO:0008206 9.56 ATP8B1 NR1H4
9 drug transmembrane transport GO:0006855 9.56 ABCB4 ABCC2 ABCC3 ATP8B1
10 glutathione catabolic process GO:0006751 9.54 GGT1 GGT2
11 ATP hydrolysis coupled anion transmembrane transport GO:0099133 9.54 ABCC2 ABCC3 ABCC4
12 leukotriene D4 biosynthetic process GO:1901750 9.52 GGT1 GGT2
13 drug export GO:0046618 9.51 ABCB4 NR1I2
14 xenobiotic transport GO:0042908 9.5 ABCB4 ABCC3 NR1I2
15 bile acid secretion GO:0032782 9.49 ABCB4 SLC51B
16 response to antineoplastic agent GO:0097327 9.48 ABCB4 ABCC2
17 regulation of bile acid biosynthetic process GO:0070857 9.46 CYP7A1 NR1H4
18 canalicular bile acid transport GO:0015722 9.33 ABCB11 ABCC2 ABCC3
19 bile acid and bile salt transport GO:0015721 9.28 ABCB11 ABCC3 ALB ATP8B1 NR1H4 SLC10A1

Molecular functions related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 ATPase activity GO:0016887 9.72 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4
2 transmembrane transporter activity GO:0022857 9.71 ABCC2 ABCC3 SLC25A13 SLC51B
3 organic anion transmembrane transporter activity GO:0008514 9.54 ABCC2 ABCC3 SLCO1A2
4 transcription factor activity, direct ligand regulated sequence-specific DNA binding GO:0098531 9.52 NR1H4 NR1I2
5 glutathione hydrolase activity GO:0036374 9.51 GGT1 GGT2
6 thyroid hormone receptor activity GO:0004887 9.49 NR1H4 NR1I2
7 xenobiotic transmembrane transporting ATPase activity GO:0008559 9.48 ABCB4 ABCC3
8 bile acid:sodium symporter activity GO:0008508 9.46 SLC10A1 SLC10A2
9 organic acid transmembrane transporter activity GO:0005342 9.43 SLC10A1 SLC10A2
10 bile acid transmembrane transporter activity GO:0015125 9.33 SLC10A1 SLC51B SLCO1A2
11 bile acid-exporting ATPase activity GO:0015432 9.26 ABCB11 ABCC3
12 ATPase-coupled anion transmembrane transporter activity GO:0043225 9.13 ABCC2 ABCC3 ABCC4
13 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.02 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4

Sources for Bile Duct Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....